National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Lacosamide (Vimpat ®)

Vimpat ® is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.  The Applicant is seeking reimbursement for an extension to the product license to cover children (≥4 years of age) and adolescents (≤ 15 years of age).

NCPE Assessment Process Complete
Rapid review commissioned 11/09/2017
Rapid review completed 31/10/2017
Rapid Review outcome A full pharmacoeconomic evaluation is recommended at the submitted price.